Physician profile
Eric Windsor Weidmann
NPI 1922002617
$13,196.70
in general payments reported to CMS, 2019-2025
54 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,486 · 2020: $3,120 · 2021: $2,688 · 2022: $1,325 · 2023: $1,578.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,464 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,464.06 |
| Education | $114.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,560.60 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Viiv Healthcare Company | $1,615.27 | 2019-2023 | Apretude |
| Abbvie INC. | $973.69 | 2019-2023 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $961.99 | 2019-2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $832.48 | 2019-2023 | |
| Lilly USA, LLC | $772.97 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $650.35 | 2019-2023 | Jardiance, Synjardy |
| Sanofi-Aventis U.S. LLC | $565.66 | 2019-2022 | |
| Gilead Sciences, INC. | $523.46 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $406.23 | 2019-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $376.67 | 2019-2023 | Xifaxan |
| Amgen INC. | $302.44 | 2019-2022 | |
| Pfizer INC. | $244.27 | 2019-2023 | |
| Amarin Pharma, INC. | $221.77 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $195.33 | 2019-2021 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Weidmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.